Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss(National Cancer Institute), James L. Gulley(National Institutes of Health), Italia Grenga(National Cancer Institute), Liang Cao(National Human Genome Research Institute), Jennifer L. Marté(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Christoph Helwig(Merck KGaA, Darmstadt (Germany)), Ravi A. Madan(National Cancer Institute), Renee N. Donahue(National Institutes of Health), Zhigang Kang(Center for Drug Evaluation and Research), Jeffrey Schlom(National Cancer Institute), Christopher R. Heery(National Cancer Institute), Elizabeth Lamping(National Cancer Institute), Olaf Christensen(Merck Serono S.p.A. (Italy)), Lisa Mahnke(Merck Serono S.p.A. (Italy))
Cited by 415
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast Tumors
|Hybridoma|1984|580
A spectrum of monoclonal antibodies reactive with human mammary tumor cells.
|Proceedings of the National Academy of Sciences|1981|563